Core Insights - STAAR Surgical Company, a leader in phakic IOLs, announced preliminary net sales results for Q3 2025, ending September 26, 2025 [1] Company Performance - The announcement of preliminary net sales is made ahead of the quarterly earnings report to provide stockholders with additional insights into the company's performance [1]

Core Viewpoint - Broadwood Partners and its affiliates announced that Institutional Shareholder Services Inc. (ISS) recommended shareholders of STAAR Surgical Company to vote "AGAINST" the proposed acquisition by Alcon Inc. [1] Group 1 - ISS is the third proxy advisory firm to recommend against the proposed merger [1]

Core Points - Broadwood Partners, L.P. and its affiliates have commented on STAAR Surgical Company's recent filing with the SEC regarding a supplement to its definitive proxy statement related to the proposed acquisition by Alcon Inc. [1] Company Summary - Broadwood Partners owns 27.5% of STAAR Surgical Company [1]

Group 1 - Broadwood Partners, L.P. and its affiliates own 27.5% of STAAR Surgical Company's outstanding common shares [1] - Broadwood is urging fellow shareholders to vote against the proposed acquisition of STAAR by Alcon Inc. [1] - The acquisition terms were announced on August 5, 2025 [1]

Core Viewpoint - STAAR Surgical Company strongly disagrees with the recommendation issued by Glass, Lewis & Co. regarding its pending merger with Alcon [1] Company Summary - STAAR Surgical is a global leader in phakic IOLs, specifically with its EVO family of Implantable Collamer® Lenses for vision correction [1] - The company is currently involved in a merger process with Alcon, a significant player in the eye care industry [1]

Core Points - Broadwood Partners and its affiliates announced that Glass Lewis, a prominent proxy advisory firm, recommended STAAR Surgical Company shareholders vote "AGAINST" the proposed acquisition by Alcon Inc. [1] Group 1 - Glass Lewis's recommendation highlights concerns regarding the acquisition terms announced on August 5, 2025 [1]

Core Viewpoint - Defender Capital opposes the proposed acquisition of STAAR Surgical Company by Alcon Inc., arguing that the offer of $28 per share significantly undervalues STAAR, especially in light of a previous offer of $58 per share that was rejected by the STAAR Board of Directors just sixteen months ago [1]. Group 1 - Defender Capital has been a significant shareholder of STAAR for over ten years and believes in the substantial value of the company [1]. - The recent positive projections and outlook from STAAR's management provide no compelling reason to sell the company at the proposed valuation [2]. - Defender Capital expresses disappointment that the STAAR Board is pursuing a transaction that does not reflect the standalone business prospects of STAAR [2].

Core Viewpoint - STAAR Surgical Company is recognized by independent industry analysts as having a favorable merger with Alcon, which offers compelling cash value for STAAR stockholders [1] Company Summary - STAAR Surgical Company is a global leader in phakic IOLs, specifically with its EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction [1] - The merger with Alcon is viewed as the best path forward for STAAR stockholders, providing a certain and premium cash value [1] Industry Summary - The commentary from independent analysts highlights the positive outlook for STAAR's stockholders following the merger with Alcon [1]

Core Viewpoint - Broadwood Partners, L.P. and its affiliates, holding approximately 27.5% of STAAR Surgical Company's outstanding common stock, are urging stockholders to vote against the proposed acquisition by Alcon Inc. on the terms announced on August 5, 2025 [1]. Group 1 - Broadwood has published a presentation to support its position against the acquisition [1]. - The acquisition is being contested on the basis of the terms outlined in the announcement made on August 5, 2025 [1].

Core Viewpoint - Kaskela Law LLC is investigating the fairness of the shareholder buyout offer made to STAAR Surgical Company, particularly focusing on whether the proposed price of $28.00 per share is adequate compared to the company's 52-week high of $38.60 per share, and concerns regarding conflicts of interest in the sales process [1]. Summary by Relevant Sections Shareholder Buyout Offer - STAAR Surgical Company has agreed to be acquired by Alcon at a price of $28.00 per share, which is significantly lower than its 52-week high of $38.60 per share [1]. - The investigation by Kaskela Law LLC aims to determine if the buyout proposal is fair and provides sufficient monetary consideration for STAAR's investors [1]. Conflicts of Interest - Initial findings from the investigation suggest that there are significant conflicts of interest associated with the transaction, raising concerns about the fairness of the sales process and the consideration offered to shareholders [1]. - STAAR's largest shareholder has expressed serious concerns regarding the fairness and integrity of the sales process, indicating that the acquisition may not be in the best interest of STAAR's shareholders [1].